Bizhongxiao decoction improves the activities of daily living in patients with rheumatoid arthritis
YQ Jiang,QH Liang,XC Liu,XG Xiong,R Fan,J Wang
DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.12.040
2007-01-01
Abstract:AIM: To observe the alteration of bizhongxiao decoction (BZXD) on the range of active movement and activities of daily living (ADL) in patients with rheumatoid arthritis (RA), and further investigate the clinical curative effect of BZXD. METHODS: Between October 2004 and May 2006, eighty-six patients with RA on active phase were enrolled from the Institute of Combined Traditional Chinese and Western Medicine in Xiangya Hospital, and were divided into two groups: BZXD treated group (n =44) and control group (n =42). Treated group: BZXD was consisted of 15 g Hedyotic diffusa, 15 g Danshen Root, 30 g pearl barley, 15 g Fortune's Drynaria Rhizome, 20 g Chinese Starjasmine Stem, 30 g zhongjiefeng, etc. All the herbs were purchased by Dispensary of Traditional Chinese Medicine in Xiangya Hospital and then decocted routinely with the concentration of 1.038 g/mL, one preparation daily for two oral administrations. Control group adopted the combination of Methotrexate (20 mg, once per week, taken orally with equal folic acid) and Nimesulide (0.1 g, twice daily). Both groups were treated for 3 months as one course. Symptoms and signs, such as index of joint pain, joint tenderness, arthroncus, as well as morning stiffness time and grip strength were evaluated in accordance with the criteria of American Rheumatism Association. ADL before and after treatment was determined with modified Barthel index, including 10 items of taking a bath, decorating (5 points for each), having meal, dressing, going toilet, sedes controls, urination controls, upstairs and downstairs (10 points for each), transferring between beds and chairs, walking for 45 minutes (15 points for each). RESULTS: All 86 RA patients were involved in the result analysis. After 3-month treatment, the index of joint pain, joint tenderness, arthroncus, joint functional impairment index, morning stiffness time, average grip strength of both hands and ADL were significantly ameliorated in BZXD treated group and control group compared with those before treatment (P < 0.01, 0.05). Compared with the control group, the indices above were improved notably in BZXD treated group (P < 0.01-0.05). CONCLUSION: The treatment with BZXD, non-steroidal anti-inflammatory drug and the combination of Methotrexate and Nimesulide tablets can all ameliorate the range of active movement and improve ADL of RA patients, and the effects of BZXD are obviously better.